Zogenix Inc (ZGNX):企業の財務・戦略的SWOT分析

【英語タイトル】Zogenix Inc (ZGNX) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(DATA904C9447)・商品コード:DATA904C9447
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:59
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Zogenix Inc (ZGNX) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Zogenix Inc (Zogenix) is a pharmaceutical company with focus on central nervous system (CNS) disorders. It develops and commercializes therapies for rare CNS disorders. The company’s lead product candidate ZX008 (low dose fenfluramine) is intended for the treatment of Dravet syndrome and Lennox-Gastaut syndrome (LGS). ZX008 is in Phase 3 clinical trials and has orphan drug designation in the US and EU and secured Fast Track designation and breakthrough therapy designation from the US FDA. The company operates in the UK through its subsidiary Zogenix International, Ltd. Zogenix is headquartered in Emeryville, California, the US.

Zogenix Inc Key Recent Developments

Sep 04,2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS]
Aug 30,2018: Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
Aug 06,2018: Zogenix provides corporate update and reports second quarter financial results
Jul 02,2018: Zogenix Appoints Ashish Sagrolikar As New Global Chief Commercial Officer
May 09,2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Zogenix Inc – Key Facts 6
Zogenix Inc – Key Employees 7
Zogenix Inc – Key Employee Biographies 8
Zogenix Inc – Major Products and Services 9
Zogenix Inc – History 10
Zogenix Inc – Company Statement 11
Zogenix Inc – Locations And Subsidiaries 13
Head Office 13
Other Locations & Subsidiaries 13
Section 2 – Company Analysis 14
Company Overview 14
Zogenix Inc – Business Description 15
R&D Overview 15
Zogenix Inc – SWOT Analysis 16
SWOT Analysis – Overview 16
Zogenix Inc – Strengths 16
Zogenix Inc – Weaknesses 17
Zogenix Inc – Opportunities 18
Zogenix Inc – Threats 19
Zogenix Inc – Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios – Capital Market Ratios 21
Financial Ratios – Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios – Interim Ratios 26
Financial Ratios – Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Zogenix Inc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS] 31
Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS] 35
Sep 04, 2018: Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome[Newswire : Healthcare - GNW RSS] 39
Aug 06, 2018: Zogenix provides corporate update and reports second quarter financial results 43
May 09, 2018: Zogenix Provides Corporate Update and Reports First Quarter Financial Results 45
Mar 06, 2018: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results 47
Nov 07, 2017: Zogenix Provides Corporate Update and Reports Third Quarter 2017 Financial Results 49
Aug 08, 2017: Zogenix Provides Corporate Update and Reports Second Quarter 2017 Financial Results 51
May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 53
May 04, 2017: Zogenix Q1 net loss increases 54
Section 6 – Appendix 55
Methodology 55
Ratio Definitions 55
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Zogenix Inc, Key Facts 6
Zogenix Inc, Key Employees 7
Zogenix Inc, Key Employee Biographies 8
Zogenix Inc, Major Products and Services 9
Zogenix Inc, History 10
Zogenix Inc, Other Locations 13
Zogenix Inc, Subsidiaries 13
Zogenix Inc, Key Competitors 20
Zogenix Inc, Ratios based on current share price 21
Zogenix Inc, Annual Ratios 22
Zogenix Inc, Annual Ratios (Cont...1) 23
Zogenix Inc, Annual Ratios (Cont...2) 24
Zogenix Inc, Interim Ratios 26
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Zogenix Inc, Recent Deals Summary 30
Currency Codes 55
Capital Market Ratios 55
Equity Ratios 56
Profitability Ratios 56
Cost Ratios 57
Liquidity Ratios 57
Leverage Ratios 58
Efficiency Ratios 58

List of Figures
Zogenix Inc, Performance Chart (2013 - 2017) 25
Zogenix Inc, Ratio Charts 27
Zogenix Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Zogenix Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

★調査レポート[Zogenix Inc (ZGNX):企業の財務・戦略的SWOT分析] (コード:DATA904C9447)販売に関する免責事項を必ずご確認ください。
★調査レポート[Zogenix Inc (ZGNX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆